NTRK1 and pancreatic adenocarcinoma: ERBB2 amplification (3.1%), especially in the absence of BRAF/KRAS/NRAS activating mutation (2.5%), is an actionable marker for HER2-targeted treatment approaches.14-16 Approximately 6% of pancreatic adenocarcinoma reports identified established predictive markers (inactivating BRCA1/2 alteration 3.7%, TMB ≥ 10 mut/Mb 1.5%, inactivating PALB2 alteration 0.6%, MSI-high 0.5%, and NTRK1/2/3 fusion 0.1%).